Condition: T-cell Non-Hodgkin Lymphoma · Lymphoma, Extranodal NK-T-Cell · Sponsor: Keimyung University Dongsan Medical Center
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.
This description comes directly from the study's public registry record.
Young Rok Do, MD., Ph.D. · +82-10-3541-1160 · dyr1160@dsmc.or.kr
Ji Hyun Lee, MD., Ph.D. · +82-10-9397-5694 · hidrleejh@dau.ac.kr
Always discuss trial participation with your own doctor first.
| Dong-A University | Busan, South Korea | Recruiting |
| Keimyung University Dongsan Medical Center | Daegu, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02859402